The CBD Craze: Still Only the Beginning Consumers are craving hemp products,and brands are set to deliver despite regulatory uncertainty

摘要

Few nutraceutical ingredients have burst onto the U.S.market quite like hemp and cannabidiol(CBD),which were propelled by the passage of the Agriculture Improvement Act of 2018(also known as the Farm Bill).The regulation declassified hemp with less than 0.3% THC as a Schedule I controlled substance and legalized cultivation.However,the US.Food and Drug Administration(FDA) continues to regulate cannabis products under the Food,Drug,and Cosmetic Act.One of the many components of hemp and cannabis,CBD has been marketed as a panacea for modern living,in both topical and ingestible product formulations,drawing warning letters that have called out bogus health claims and the ire of more modest brands.Given federal statute regarding investigational new drug trials that might preclude a New Dietary Ingredient(NDI) Notification,FDA has stated that CBD cannot legally be sold as a dietary supplement in the U.S.However,at the same time,it has mostly exercised enforcement discretion,except for cases of egregious health claims or serious good manufacturing practice(GMP) violations,while it explores legal pathways to market.